{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:36Z","timestamp":1793394876216,"version":"4.5.0"},"reference-count":383,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Macao Science and Technology Development Fund","doi-asserted-by":"publisher","award":["092\/2012\/A3"],"award-info":[{"award-number":["092\/2012\/A3"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejmech.2018.09.027","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T01:49:59Z","timestamp":1536803399000},"page":"502-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":521,"special_numbering":"C","title":["Side effects of methotrexate therapy for rheumatoid arthritis: A\u00a0systematic review"],"prefix":"10.1016","volume":"158","author":[{"given":"Wanying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.09.027_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0049-0172(90)90060-S","article-title":"Methotrexate: mechanism of action in rheumatoid arthritis","volume":"20","author":"Segal","year":"1990","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0889-857X(21)00061-2","article-title":"Adverse reactions and major toxicities","volume":"20","author":"Methotrexate","year":"1994","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2018.09.027_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/03009749609065644","article-title":"Methotrexate update","volume":"25","author":"Kremer","year":"1996","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/art.1780391203","article-title":"Molecular therapeutics: methotrexate and its mechanism of action","volume":"39","author":"Cronstein","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(83)90477-1","article-title":"Methotrexate therapy in rheumatoid arthritis: 15 years experience","volume":"75","author":"Hoffmeister","year":"1983","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib7","first-page":"314","article-title":"Methotrexate: a perspective of its use in the treatment of rheumatic diseases","volume":"100","author":"Willkens","year":"1982","journal-title":"J.\u00a0Lab. Clin. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.09.027_bib12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial","volume":"66","author":"Burmester","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"issue":"53","key":"10.1016\/j.ejmech.2018.09.027_bib15","doi-asserted-by":"crossref","first-page":"30061","DOI":"10.1039\/C8RA04886J","article-title":"Network pharmacology combined with functional metabolomics discover bile acid metabolism as a promising target for mirabilite against colorectal cancer","volume":"8","author":"Sun","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.09.027_bib16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","article-title":"A\u00a0meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal","volume":"44","author":"Choy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejmech.2018.09.027_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10067-014-2794-9","article-title":"Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study","volume":"34","author":"Santos-Moreno","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/qjmed\/94.6.309","article-title":"Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice","volume":"94","author":"Grove","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.ejmech.2018.09.027_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 Update","volume":"46","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib20","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/ard.2010.139345","article-title":"Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial","volume":"70","author":"Kremer","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/rheumatology\/36.5.535","article-title":"Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study","volume":"36","author":"Bologna","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2015","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.ejmech.2018.09.027_bib24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Eeffect of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis","volume":"333","author":"Van Der Heijde","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.09.027_bib25","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","article-title":"Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E","volume":"68","author":"Visser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00290521","article-title":"Long term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis","volume":"15","author":"Schnabel","year":"1995","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.ejmech.2018.09.027_bib27","first-page":"1864","article-title":"Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice","volume":"27","author":"Wluka","year":"2000","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10067-014-2546-x","article-title":"Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort","volume":"33","author":"Nikiphorou","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib29","first-page":"1850","article-title":"Adverse effects of low dose methotrexate therapy in rheumatoid arthritis","volume":"20","author":"McKendry","year":"1993","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/anr.1780320603","article-title":"Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment","volume":"32","author":"Alarcon","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/art.1780371013","article-title":"Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study","volume":"37","author":"Weinblatt","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-0172(91)90032-U","article-title":"Long-term methotrexate therapy for rheumatoid arthritis","volume":"20","author":"Scully","year":"1991","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/anr.1780320603","article-title":"Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment","volume":"32","author":"Alarc\u00f3an","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib34","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(58)92307-9","article-title":"Leukaemogens","volume":"2","author":"Abbatt","year":"1958","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.09.027_bib35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/ard.23.6.480","article-title":"An association between the rheumatic diseases and the reticuloses","volume":"23","year":"1964","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9343(85)90242-6","article-title":"Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland","volume":"78","author":"Hakulinen","year":"1985","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.41.Suppl_1.34","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"41","author":"Isom\u00e4ki","year":"1982","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.43.2.128","article-title":"Cancer morbidity in rheumatoid arthritis","volume":"43","author":"Prior","year":"1984","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2018.09.027_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/rheumatology\/31.4.253","article-title":"Long-term second-line treatment: a prospective drug survival study","volume":"31","author":"Wijnands","year":"1992","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0049-0172(95)80009-3","article-title":"Infections during low-dose methotrexate treatment in rheumatoid arthritis","volume":"24","author":"Boerbooms","year":"1995","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib42","first-page":"103","article-title":"Methotrexate therapy in rheumatoid arthritis","volume":"32","author":"Wilke","year":"1986","journal-title":"Current status. Drugs."},{"key":"10.1016\/j.ejmech.2018.09.027_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/art.1780360303","article-title":"The relative toxicity of disease-modifying antirheumatic drugs","volume":"36","author":"Fries","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib44","first-page":"25","article-title":"Methotrexate in rheumatoid arthritis","volume":"47","author":"Bannwarth","year":"1994","journal-title":"An update. Drugs."},{"key":"10.1016\/j.ejmech.2018.09.027_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/anr.1780320202","article-title":"Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples","volume":"32","author":"Kremer","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib46","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/art.1780380904","article-title":"Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables","volume":"38","author":"Kremer","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib47","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/art.1780401016","article-title":"Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review","volume":"40","author":"Kremer","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib48","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/anr.1780321214","article-title":"Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy","volume":"32","author":"Weinblatt","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib49","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","volume":"13","author":"Kivity","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejmech.2018.09.027_bib50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","article-title":"Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis","volume":"47","author":"Wessels","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib51","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.34342","article-title":"Methotrexate increases expression of cell cycle checkpoint genes via JNK activation","volume":"64","author":"Spurlock","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib52","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/art.30457","article-title":"Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK","volume":"63","author":"Spurlock","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib53","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pbc.20471","article-title":"Methotrexate induces cell swelling and necrosis in renal tubular cells","volume":"46","author":"Gronroos","year":"2006","journal-title":"Pediatr. Blood Canc."},{"key":"10.1016\/j.ejmech.2018.09.027_bib54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol. Rev."},{"issue":"34","key":"10.1016\/j.ejmech.2018.09.027_bib55","doi-asserted-by":"crossref","first-page":"19238","DOI":"10.1039\/C8RA00978C","article-title":"High-throughput metabolomics used to identify potential therapeutic targets of Guizhi Fuling Wan against endometriosis of cold coagulation and blood stasis","volume":"8","author":"Wu","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.09.027_bib56","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib58","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1039\/C6RA27461G","article-title":"Exploration of metabolite signatures using high-throughput mass spectrometry coupled with multivariate data analysis","volume":"7","author":"Zhang","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.09.027_bib59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/keu279","article-title":"Methotrexate-mediated inhibition of nuclear factor \u03baB activation by distinct pathways in T cells and fibroblast-like synoviocytes","volume":"54","author":"Spurlock","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"113","key":"10.1016\/j.ejmech.2018.09.027_bib60","doi-asserted-by":"crossref","first-page":"112534","DOI":"10.1039\/C6RA24267G","article-title":"Chemometrics strategy coupled with high resolution mass spectrometry for analyzing and interpreting comprehensive metabolomic characterization of hyperlipemia","volume":"6","author":"Zhao","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.09.027_bib61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","article-title":"Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib62","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/1529-0131(199811)41:11<2032::AID-ART19>3.0.CO;2-J","article-title":"Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes","volume":"41","author":"Seitz","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0162-3109(99)00185-X","article-title":"Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis","volume":"47","author":"Sung","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/1529-0131(199801)41:1<48::AID-ART7>3.0.CO;2-K","article-title":"Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in\u00a0vitro by competitive reverse transcriptase-polymerase chain react","volume":"41","author":"Constantin","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3420143","article-title":"Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?","volume":"342","author":"Fairbanks","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.09.027_bib66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-1-4615-2584-4_89","article-title":"The antiinflammatory effects of methotrexate are mediated by adenosine","volume":"370","author":"Cronstein","year":"1994","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib67","series-title":"Cancer Chemotherapy and Biotherapy Priciple and Practice","author":"Chabner","year":"2005"},{"key":"10.1016\/j.ejmech.2018.09.027_bib68","doi-asserted-by":"crossref","first-page":"28128","DOI":"10.1074\/jbc.M109.041483","article-title":"Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways","volume":"284","author":"Crabtree","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib69","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1074\/jbc.M805403200","article-title":"Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status insights from cells with TET-regulated GTP cyclohydrolasei expression","volume":"284","author":"Crabtree","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib70","doi-asserted-by":"crossref","first-page":"12691","DOI":"10.1074\/jbc.M809295200","article-title":"Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells","volume":"284","author":"Sugiyama","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib71","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1073\/pnas.0409594102","article-title":"Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase","volume":"102","author":"Chalupsky","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2018.09.027_bib72","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","article-title":"Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates","volume":"260","author":"Allegra","year":"1985","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib73","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2018.09.027_bib74","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/S0024-3205(00)00559-2","article-title":"Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line","volume":"66","author":"Budzik","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2018.09.027_bib76","first-page":"11","article-title":"Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates","volume":"26","author":"Sierra","year":"1999","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib77","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/ard.51.3.424","article-title":"Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis","volume":"51","author":"Capell","year":"1992","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib78","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/clpt.1984.47","article-title":"Low-dose methotrexate kinetics in arthritis","volume":"35","author":"Edelman","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2018.09.027_bib79","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2018.09.027_bib80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00003088-200342020-00003","article-title":"Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases","volume":"42","author":"Grim","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2018.09.027_bib81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002280050404","article-title":"Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment","volume":"53","author":"Chladek","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib82","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2230.1985.tb02548.x","article-title":"Impact of methotrexate therapy on the folate status of psoriatic patients","volume":"10","author":"Hendelj","year":"1985","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard.53.7.475","article-title":"Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis","volume":"53","author":"Lebbe","year":"1994","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib84","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib85","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0083-6729(03)01012-4","article-title":"Membrane transport of folates","volume":"66","author":"Matherly","year":"2003","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.ejmech.2018.09.027_bib87","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/rheumatology\/28.5.422","article-title":"Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis","volume":"28","author":"Tishler","year":"1989","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib88","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/art.1780371210","article-title":"Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients","volume":"37","author":"Bologna","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib89","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jps.2600600803","article-title":"Methotrexate pharmacokinetics","volume":"60","author":"Bischoff","year":"1971","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib90","series-title":"Version Details - Trove.","article-title":"Applied pharmacokinetics\u202f: principles of therapeutic drug monitoring","author":"Jusko","year":"1992"},{"key":"10.1016\/j.ejmech.2018.09.027_bib91","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3899\/jrheum.130066","article-title":"Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue","volume":"40","author":"Stamp","year":"2013","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2018.09.027_bib93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11095-007-9407-0","article-title":"Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates","volume":"25","author":"Van Wert","year":"2008","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2018.09.027_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197803010-00001","article-title":"Clinical pharmacokinetics of methotrexate","volume":"3","author":"Shen","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2018.09.027_bib95","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jps.2600790907","article-title":"Effect of aspirin and sulindac on methotrexate clearance","volume":"79","author":"Furst","year":"1990","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib96","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2125.1993.tb04158.x","article-title":"The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis","volume":"35","author":"Seideman","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib97","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.leu.2403703","article-title":"Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study","volume":"19","author":"Whitehead","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2018.09.027_bib98","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00007691-199604000-00004","article-title":"Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients","volume":"18","author":"Edno","year":"1996","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejmech.2018.09.027_bib99","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.1780290703","article-title":"Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib100","first-page":"S40","article-title":"Methotrexate transport mechanisms: the basis for targeted drug delivery and \u03b2-folate-receptor-specific treatment","volume":"28","author":"Fiehn","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib101","first-page":"G13","article-title":"Hepatic uptake of albumin-bound substances: albumin receptor concept","volume":"245","author":"Ockner","year":"1983","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib102","first-page":"473","article-title":"Methotrexate in rheumatoid arthritis","volume":"58","author":"Swierkot","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2018.09.027_bib103","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib104","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1373\/49.10.1632","article-title":"HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib105","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11926-010-0120-3","article-title":"Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?","volume":"12","author":"Danila","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.ejmech.2018.09.027_bib106","first-page":"1709","article-title":"Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy","volume":"35","author":"Hornung","year":"2008","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib107","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2013-203725","article-title":"Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis","volume":"74","author":"de Rotte","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib108","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.24653","article-title":"Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment","volume":"60","author":"Stamp","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib109","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/bjc.1973.190","article-title":"Methotrexate in liver and bile after intravenous dosage in man","volume":"28","author":"Creaven","year":"1973","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2018.09.027_bib110","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00043426-199711000-00008","article-title":"Accumulation of methotrexate in systemic tissues after intrathecal administration","volume":"19","author":"Bleyer","year":"1997","journal-title":"J.\u00a0Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib111","first-page":"38","article-title":"Pharmacokinetics and renal-function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy","volume":"22","author":"Kremer","year":"1995","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib112","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI107362","article-title":"Threshold methotrexate concentration for in\u00a0vivo inhibition of DNA synthesis in normal and tumorous target tissues","volume":"52","author":"Chabner","year":"1973","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2018.09.027_bib113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00546719","article-title":"Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption","volume":"26","author":"Hendel","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2018.09.027_bib114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/C6MB00742B","article-title":"High-throughput metabolomics approach reveals new mechanistic insights for drug response of phenotypes of geniposide towards alcohol-induced liver injury by using liquid chromatography coupled to high resolution mass spectrometry","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ejmech.2018.09.027_bib115","first-page":"203","article-title":"Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"21","author":"Anaya","year":"1994","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib116","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.1780330620","article-title":"Biliary elimination of low-dose methotrexate in humans","volume":"33","author":"Nuernberg","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib117","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00546716","article-title":"Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker","volume":"26","author":"Hendel","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib118","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0950-3579(05)80008-1","article-title":"Methotrexate-the rapidly acting drug","volume":"4","author":"Songsiridej","year":"1990","journal-title":"Bailliere\u2019s Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib119","first-page":"188","article-title":"Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis","volume":"18","author":"Singh","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"issue":"1","key":"10.1016\/j.ejmech.2018.09.027_bib120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/bmc.3453","article-title":"Mass spectrometry-based metabolomics: applications to biomarker and metabolic pathway research","volume":"30","author":"Zhang","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejmech.2018.09.027_bib121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.1989.00390030137027","article-title":"Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients","volume":"149","author":"McKendry","year":"1989","journal-title":"Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2018.09.027_bib122","article-title":"Metabolomics and proteomics annotate therapeutic properties of geniposide: targeting and regulating multiple perturbed pathways","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.09.027_bib123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00302669","article-title":"Tolerability of methotrexate starting with 15 or 25 mg\/week for rheumatoid arthritis","volume":"14","author":"Schnabel","year":"1994","journal-title":"Rheumatol. Int."},{"issue":"9","key":"10.1016\/j.ejmech.2018.09.027_bib124","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mrc.3985","article-title":"NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis","volume":"51","author":"Zhang","year":"2013","journal-title":"Magn. Reson. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib125","first-page":"1881","article-title":"Longterm treatment of destructive rheumatoid arthritis with methotrexate","volume":"24","author":"Rau","year":"1997","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0049-0172(94)90027-2","article-title":"Low-dose methotrexate in rheumatic diseases-Efficacy, side effects, and risk factors for side effects","volume":"23","author":"Schnabel","year":"1994","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib127","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00280-006-0339-x","article-title":"Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma","volume":"59","author":"Gerber","year":"2007","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","article-title":"The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions","volume":"44","author":"Kinder","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/art.1780350202","article-title":"Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update","volume":"35","author":"Weinblatt","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib130","first-page":"S97","article-title":"Methotrexate: anti-inflammatory or immunosuppressive?","volume":"11","author":"van de Putte","year":"1993","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib131","first-page":"104","article-title":"Methotrexate hepatotoxicity in patients with rheumatoid arthritis","volume":"2","author":"Sotoudehmanesh","year":"2010","journal-title":"Middle East J. Dig. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib132","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000356817","article-title":"Life-threatening gastrointestinal mucosal necrosis during methotrexate treatment for rheumatoid arthritis","volume":"7","author":"Tsukada","year":"2013","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib133","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijscr.2016.12.012","article-title":"Methotrexate-associated primary hepatic malignant lymphoma following hepatectomy: a case report","volume":"31","author":"Takei","year":"2017","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.ejmech.2018.09.027_bib134","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/s10165-010-0349-8","article-title":"Successful treatment of steroid-resistant methotrexate-induced interstitial pneumonia with peripherally administered ulinastatin","volume":"21","author":"Yamazaki","year":"2011","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/2348-3334.196068","article-title":"Pancytopenia and stomatitis induced by low-dose methotrexate use","volume":"4","author":"Yildiz","year":"2017","journal-title":"CHRISMED J. Health Res."},{"key":"10.1016\/j.ejmech.2018.09.027_bib136","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/MJT.0000000000000486","article-title":"Fatal cytopenia induced by low-dose methotrexate in elderly with rheumatoid arthritis. Identification of risk factors","volume":"24","author":"Mameli","year":"2017","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.ejmech.2018.09.027_bib137","first-page":"549","article-title":"Is methotrexate nephrotoxic?\u202f: dose-dependency, comorbidities and comedication","volume":"70","author":"Erdbrugger","year":"2011","journal-title":"Z.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib138","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.joms.2013.09.013","article-title":"Epstein-Barr virus-positive oral ulceration simulating hodgkin lymphoma in a patient treated with methotrexate: case report and review of the literature","volume":"72","author":"Naidu","year":"2014","journal-title":"J.\u00a0Oral Maxillofac. Surg."},{"issue":"4","key":"10.1016\/j.ejmech.2018.09.027_bib139","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ptr.5032","article-title":"Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine","volume":"28","author":"Zhang","year":"2014","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2018.09.027_bib140","doi-asserted-by":"crossref","first-page":"R217","DOI":"10.1186\/ar4413","article-title":"Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis","volume":"15","author":"Bulatovi\u0107 \u0106alasan","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejmech.2018.09.027_bib141","doi-asserted-by":"crossref","first-page":"65022","DOI":"10.18632\/oncotarget.17531","article-title":"Metabolic characterization and pathway analysis of berberine protects against prostate cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.09.027_bib142","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib143","first-page":"S95","article-title":"Side effects and management of side effects of methotrexate in rheumatoid arthritis","volume":"28","author":"Albrecht","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib144","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib145","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2018.09.027_bib146","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/ac202828r","article-title":"Pattern recognition approaches and computational systems tools for ultra performance liquid chromatography-mass spectrometry-based comprehensive metabolomic profiling and pathways analysis of biological data sets","volume":"84","author":"Wang","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib147","first-page":"36","article-title":"The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials","volume":"25","author":"Ortiz","year":"1998","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib148","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib149","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jdcr.2016.02.002","article-title":"Methotrexate-induced CD30+ T-cell lymphoproliferative disorder of the oral cavity","volume":"2","author":"Saleh","year":"2016","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.ejmech.2018.09.027_bib150","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.12743","article-title":"Resolution of methotrexate-induced Epstein-Barr virus-associated mucocutaneous ulcer","volume":"165","author":"Sadasivam","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib151","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer\u2014a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib152","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.30107","article-title":"The incidence of gastrointestinal perforations among rheumatoid arthritis patients","volume":"63","author":"Curtis","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib153","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/pgs.13.244","article-title":"SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients","volume":"15","author":"Lima","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejmech.2018.09.027_bib154","first-page":"1","article-title":"Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?","volume":"6634","author":"Kromann","year":"2014","journal-title":"J.\u00a0Dermatol. Treat."},{"issue":"8","key":"10.1016\/j.ejmech.2018.09.027_bib155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1074\/mcp.M111.016006","article-title":"Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease","volume":"11","author":"Wang","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ejmech.2018.09.027_bib156","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s40265-015-0486-7","article-title":"Optimizing methotrexate treatment in rheumatoid arthritis: the case for subcutaneous methotrexate prior to biologics","volume":"75","author":"Sharma","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2018.09.027_bib157","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12325-015-0276-3","article-title":"Utilization of subcutaneous methotrexate in rheumatoid arthritis patients after failure or intolerance to oral methotrexate: a multicenter cohort study","volume":"33","author":"Branco","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2018.09.027_bib158","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/1097-0142(196604)19:4<600::AID-CNCR2820190420>3.0.CO;2-3","article-title":"Hepatotoxic effects of methotrexate","volume":"19","author":"Hersh","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2018.09.027_bib159","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/bmj.1.5750.625","article-title":"Liver damage due to methotrexate in patients with psoriasis","volume":"1","author":"Dahl","year":"1971","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2018.09.027_bib160","first-page":"978","article-title":"The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study","volume":"18","author":"Mielants","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib161","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02114393","article-title":"Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up","volume":"9","author":"Drosos","year":"1990","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.ejmech.2018.09.027_bib162","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jprot.2011.10.027","article-title":"Recent and potential developments of biofluid analyses in metabolomics","volume":"75","author":"Zhang","year":"2012","journal-title":"J\u00a0Proteomics"},{"key":"10.1016\/j.ejmech.2018.09.027_bib163","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib164","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib165","first-page":"104","article-title":"Methotrexate hepatotoxicity in patients with rheumatoid arthritis","volume":"2","author":"Sotoudehmanesh","year":"2010","journal-title":"Middle East J. Dig. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib166","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib167","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/00003495-200262040-00005","article-title":"Drugs affecting homocysteine metabolism: impact on cardiovascular risk","volume":"62","author":"Desouza","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2018.09.027_bib168","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF01324802","article-title":"The hepatic stellate (Ito) cell: its role in human liver disease","volume":"430","author":"Hautekeete","year":"1997","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejmech.2018.09.027_bib169","first-page":"197","article-title":"Hepatotoxicity of methotrexate in rheumatic diseases","volume":"3","author":"Kevat","year":"1988","journal-title":"Med. Toxicol. Adv. Drug Exp."},{"key":"10.1016\/j.ejmech.2018.09.027_bib170","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0889-857X(05)70365-3","article-title":"Methotrexate hepatotoxicity","volume":"23","author":"West","year":"1997","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2018.09.027_bib171","first-page":"233","article-title":"Drug-induced hepatotoxicity: a review","volume":"2","author":"Pandit","year":"2012","journal-title":"J.\u00a0Appl. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib172","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0192623310367806","article-title":"Protective effect of \u03b2-carotene on methotrexate\u2013induced oxidative liver damage","volume":"38","author":"Vardi","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib173","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF01308193","article-title":"Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk\/benefit ratio","volume":"30","author":"Lanse","year":"1985","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib174","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3476(99)70371-9","article-title":"The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis","volume":"134","author":"Hashkes","year":"1999","journal-title":"J.\u00a0Pediatr."},{"issue":"65","key":"10.1016\/j.ejmech.2018.09.027_bib175","doi-asserted-by":"crossref","first-page":"108760","DOI":"10.18632\/oncotarget.21897","article-title":"Dissect new mechanistic insights for geniposide efficacy on the hepatoprotection using multiomics approach","volume":"8","author":"Qiu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.09.027_bib176","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008495","article-title":"Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis","author":"Katchamart","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2018.09.027_bib177","doi-asserted-by":"crossref","first-page":"51069","DOI":"10.1039\/C7RA09522H","article-title":"Discovery and verification of the potential targets from bioactive molecules by network pharmacology-based target prediction combined with high-throughput metabolomics","volume":"7","author":"Zhang","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.09.027_bib178","article-title":"Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis","volume":"2013","author":"Patan\u00e8","year":"2013","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/j.ejmech.2018.09.027_bib179","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3899\/jrheum.090153","article-title":"Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review","volume":"37","author":"Bourr\u00e9-Tessier","year":"2010","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/pgs.12.183","article-title":"Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate","volume":"14","author":"D\u00e1vila-Fajardo","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejmech.2018.09.027_bib181","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/pgs.09.139","article-title":"Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis","volume":"11","author":"Kooloos","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejmech.2018.09.027_bib182","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00228-008-0521-7","article-title":"Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism","volume":"64","author":"Bohanec Grabar","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib183","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.080576","article-title":"Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity","volume":"36","author":"Fisher","year":"2009","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib184","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ejmech.2018.09.027_bib185","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity","volume":"37","author":"Kremer","year":"1994","journal-title":"Am. Coll. Rheumatol. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib186","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0049-0172(87)90021-7","article-title":"Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate","volume":"16","author":"Carson","year":"1987","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib187","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cca.2012.08.016","article-title":"Urine metabolomics","volume":"414","author":"Zhang","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2018.09.027_bib188","first-page":"137","article-title":"Methotrexate pneumonitis in a patient with rheumatoid arthritis","volume":"36","author":"Hsu","year":"2003","journal-title":"J.\u00a0Microbiol. Immunol. Infect."},{"key":"10.1016\/j.ejmech.2018.09.027_bib189","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.ejmech.2018.09.027_bib190","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00216-012-6117-1","article-title":"Serum metabolomics as a novel diagnostic approach for disease: a systematic review","volume":"404","author":"Zhang","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib191","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/keg466","article-title":"Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis","volume":"43","author":"Saravanan","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib192","first-page":"2299","article-title":"Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis","volume":"24","author":"Ohosone","year":"1997","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib193","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/s10165-007-0578-7","article-title":"Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis","volume":"17","author":"Cho","year":"2007","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib194","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib195","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.fitote.2012.11.010","article-title":"Protective effects of sweroside on human MG-63 cells and rat osteoblasts","volume":"84","author":"Sun","year":"2013","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2018.09.027_bib196","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14740338.4.4.723","article-title":"Methotrexate pulmonary toxicity","volume":"4","author":"Lateef","year":"2005","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2018.09.027_bib197","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/art.1780261016","article-title":"Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis","volume":"26","author":"Engelbrecht","year":"1983","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.ejmech.2018.09.027_bib198","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/bmc.2951","article-title":"Profiling and identification of the absorbed constituents and metabolites of schisandra lignans by ultra-performance liquid chromatography coupled to mass spectrometry","volume":"27","author":"Sun","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejmech.2018.09.027_bib199","first-page":"153","article-title":"Methotrexate-induced pulmonary toxicity","volume":"20","author":"Jakubovic","year":"2013","journal-title":"Canc. Res. J."},{"key":"10.1016\/j.ejmech.2018.09.027_bib200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/rheumatology\/kem230","article-title":"Methotrexate pneumonitis precipitated by switching from oral to parenteral administration","volume":"47","author":"Collins","year":"2008","journal-title":"Rheumatology"},{"issue":"19","key":"10.1016\/j.ejmech.2018.09.027_bib201","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/jssc.201300529","article-title":"An effective method for determining the ingredients of Shuanghuanglian formula in blood samples using high-resolution LC-MS coupled with background subtraction and a multiple data processing approach","volume":"36","author":"Yan","year":"2013","journal-title":"J.\u00a0Separ. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib202","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s10067-006-0480-2","article-title":"Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis","volume":"26","author":"Kameda","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib203","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1445-5994.1995.tb02851.x","article-title":"Hazards of low dose methotrexate","volume":"25","author":"Conaghan","year":"1995","journal-title":"Aust. N. Z. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib204","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1378\/chest.91.1.96","article-title":"Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism","volume":"91","author":"Akoun","year":"1987","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2018.09.027_bib205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/01902140303768","article-title":"Methotrexate stimulates lung epithelial cells to release inflammatory cell chemotactic activities","volume":"29","author":"Koyama","year":"2003","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.ejmech.2018.09.027_bib206","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tox.2008.11.016","article-title":"Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway","volume":"256","author":"Kim","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib207","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/14740330903066734","article-title":"Mechanisms underlying methotrexate-induced pulmonary toxicity","volume":"8","author":"Kim","year":"2009","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2018.09.027_bib208","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2131\/jts.35.653","article-title":"Induction of pulmonary fibrosis by methotrexate treatment in mice lung in\u00a0vivo and in\u00a0vitro","volume":"35","author":"Ohbayashi","year":"2010","journal-title":"J.\u00a0Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib209","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarc\u00f3n","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib210","first-page":"1043","article-title":"The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis","volume":"22","author":"Golden","year":"1995","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib211","first-page":"1196","article-title":"All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database","volume":"30","author":"Watson","year":"2003","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib212","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib213","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis - a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib214","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10067-011-1758-6","article-title":"How common is methotrexate pneumonitis? A large prospective study investigates","volume":"31","author":"Sathi","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib215","first-page":"51","article-title":"Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis?","volume":"7","author":"Howes","year":"1999","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib216","series-title":"European Respiratory Monograph 46: Interstitial Lung Diseases","author":"R.MDB","year":"2009"},{"key":"10.1016\/j.ejmech.2018.09.027_bib217","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.51.2.272","article-title":"Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis","volume":"51","author":"Cook","year":"1992","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib218","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10067-006-0301-7","article-title":"Low-dose methotrexate-induced pancytopenia","volume":"26","author":"Preet Singh","year":"2007","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.ejmech.2018.09.027_bib219","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/hep.26130","article-title":"Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma","volume":"57","author":"Wang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib220","first-page":"1741","article-title":"Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate","volume":"18","author":"Ellman","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib221","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/rheumatology\/31.2.107","article-title":"A\u00a0patient with rheumatoid arthritis and lymphoma","volume":"31","author":"Donnelly","year":"1992","journal-title":"Br. J. Rheumatol."},{"issue":"3","key":"10.1016\/j.ejmech.2018.09.027_bib222","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s12010-012-0001-5","article-title":"Proteomic identification network analysis of haptoglobin as a key regulator associated with liver fibrosis","volume":"169","author":"Zhang","year":"2013","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib223","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib224","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4103\/0253-7613.121385","article-title":"Pott's disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy","volume":"45","author":"Zorlu","year":"2013","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib225","first-page":"679580","article-title":"Methotrexate induced pancytopenia","volume":"2014","author":"Gonzalez-Ibarra","year":"2014","journal-title":"Case Rep. Rheumatol."},{"issue":"4","key":"10.1016\/j.ejmech.2018.09.027_bib226","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/omi.2012.0064","article-title":"Proteomics analysis of hepatoprotective effects for scoparone using MALDI-TOF\/TOF mass spectrometry with bioinformatics","volume":"17","author":"Zhang","year":"2013","journal-title":"OMICS"},{"key":"10.1016\/j.ejmech.2018.09.027_bib227","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/0960327108094507","article-title":"Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy","volume":"27","author":"Hocaoglu","year":"2008","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib228","article-title":"Methotrexate induced pancytopenia is rare and concern for it should not limit its use","volume":"45","author":"Yazici","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib229","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.revmed.2007.03.007","article-title":"Pancytop\u00e9nie sous m\u00e9thotrexate \u00e0 faibles doses\u202f: \u00e9tude de cinq observations et revue de la litt\u00e9rature","volume":"28","author":"Serraj","year":"2007","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.ejmech.2018.09.027_bib230","first-page":"344","article-title":"Severe secondary bone marrow aplasia due to methotrexate in a patient with late onset rheumatoid arthritis","volume":"10","author":"Exp\u00f3sito P\u00e9rez","year":"2014","journal-title":"Reumatol CL\u00cdNICA (English Ed."},{"key":"10.1016\/j.ejmech.2018.09.027_bib231","first-page":"1009","article-title":"A\u00a0practical approach to avoidance of methotrexate toxicity","volume":"22","author":"Wallace","year":"1995","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib232","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0190-9622(98)70387-1","article-title":"Thrombocytopenia after a single test dose of methotrexate","volume":"39","author":"Jih","year":"1998","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib233","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Ure\u00f1a","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib234","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/keh685","article-title":"Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years","volume":"44","author":"Lim","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib235","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3949\/ccjm.62.6.351","article-title":"Methotrexate in rheumatoid arthritis: when NSAIDs fail","volume":"62","author":"Flynn","year":"1995","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib236","first-page":"1121","article-title":"Pancytopenia associated with low dose methotrexate therapy","volume":"20","author":"al-Awadhi","year":"1993","journal-title":"A\u00a0regional survey. J Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib237","first-page":"39","article-title":"Methorexate therapy in a patient with rheumatoid arthritis complicated by idiopathic thrombocytopenic purpura","volume":"2","author":"Sabiha","year":"2015","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib238","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF02229705","article-title":"Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate","volume":"15","author":"Franck","year":"1996","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib239","first-page":"1","article-title":"The hematologic toxicity of methotrexate in patients with autoimmune disorders","volume":"2","author":"Rajnics","year":"2017","journal-title":"J.\u00a0Neoplasm."},{"key":"10.1016\/j.ejmech.2018.09.027_bib240","first-page":"63","article-title":"Rheumatoid arthritis and B-cell chronic lymphocytic leukemia","volume":"20","author":"Voulgari","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib241","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154744","article-title":"Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases","volume":"11","author":"Mori","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.09.027_bib242","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s00296-013-2792-2","article-title":"Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative study","volume":"33","author":"Pamuk","year":"2013","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.ejmech.2018.09.027_bib243","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127558","article-title":"Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-acetylcysteine and N-acetylcysteine amide","volume":"10","author":"Paul","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.09.027_bib244","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group","volume":"22","author":"RACTAG","year":"1995","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib245","first-page":"973","article-title":"The effect of age on methotrexate efficacy and toxicity","volume":"18","author":"Wolfe","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib246","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/PL00011187","article-title":"Pancytopenia and colitis with Clostridium difficile in a rheumatoid arthritis patient taking methotrexate, antibiotics and non-steroidal anti-inflammatory drugs","volume":"20","author":"Nanke","year":"2001","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib247","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib248","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1345\/aph.1A052","article-title":"Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis","volume":"35","author":"Calvo-Romero","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2018.09.027_bib249","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/RHU.0b013e3181a61f2d","article-title":"Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate","volume":"15","author":"Cheung","year":"2009","journal-title":"J.\u00a0Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib250","first-page":"81","article-title":"Clinical dilemma over low-dose methotrexate therapy in dialysis patients: a case report and review of literature","volume":"8","author":"Liu","year":"2014","journal-title":"Iran. J. Kidney Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib251","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00296-011-2041-5","article-title":"Methotrexate for rheumatoid arthritis patients who are on hemodialysis","volume":"31","author":"Al-Hasani","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.ejmech.2018.09.027_bib252","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Pavy","year":"2006","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.ejmech.2018.09.027_bib253","first-page":"958","article-title":"National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study","volume":"30","author":"Thomas","year":"2003","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib254","first-page":"1126","article-title":"Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis","volume":"20","author":"Seideman","year":"1993","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib255","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/rheumatology\/kem370","article-title":"Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study","volume":"47","author":"Karie","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib256","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CNP64315","article-title":"Is low-dose methotrexate nephrotoxic? Case report and review of the literature","volume":"64","author":"Izzedine","year":"2005","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib257","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/ar3256","article-title":"Renal co-morbidity in patients with rheumatic diseases","volume":"13","author":"Anders","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejmech.2018.09.027_bib258","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib259","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","article-title":"The clinical pharmacology of methotrexate. new applications of an old drug","volume":"41","author":"Bleyer","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2018.09.027_bib260","first-page":"1126","article-title":"Renal effects of low dose methotrexate in rheumatoid arthritis","volume":"20","author":"Seideman","year":"1993","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib261","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/toxins2082055","article-title":"Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity","volume":"2","author":"Hagos","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.ejmech.2018.09.027_bib262","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bcp.12282","article-title":"Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development","volume":"77","author":"Van Meer","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib263","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib264","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","article-title":"Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine","volume":"1","author":"Abelson","year":"1983","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib265","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ard.56.2.97","article-title":"Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate","volume":"56","author":"Bologna","year":"1997","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2018.09.027_bib266","article-title":"Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.09.027_bib267","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2169\/internalmedicine.55.6156","article-title":"MYC\/BCL2 double-hit lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment","volume":"55","author":"Kurimoto","year":"2016","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib268","first-page":"1","article-title":"A\u00a0case of rheumatoid arthritis with methotrexate related lymphoproliferative diseases of the knee","author":"Abe","year":"2015","journal-title":"Mod. Rheumatol."},{"issue":"15","key":"10.1016\/j.ejmech.2018.09.027_bib269","doi-asserted-by":"crossref","first-page":"7606","DOI":"10.1021\/ac401793d","article-title":"Ultraperformance liquid chromatography-mass spectrometry based comprehensive metabolomics combined with pattern recognition and network analysis methods for characterization of metabolites and metabolic pathways from biological data sets","volume":"85","author":"Zhang","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2018.09.027_bib270","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3109\/s10165-012-0717-7","article-title":"Epstein-Barr virus and methotrexate-related CNS lymphoma in a patient with rheumatoid arthritis","volume":"23","author":"Migita","year":"2013","journal-title":"Mod. Rheumatol."},{"issue":"4","key":"10.1016\/j.ejmech.2018.09.027_bib271","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/obr.12011","article-title":"Power of metabolomics in biomarker discovery and mining mechanisms of obesity","volume":"14","author":"Zhang","year":"2013","journal-title":"Obes. Rev."},{"key":"10.1016\/j.ejmech.2018.09.027_bib272","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2169\/internalmedicine.54.3361","article-title":"Methotrexate-related primary hepatic lymphoma in a patient with rheumatoid arthritis","volume":"54","author":"Miyagawa","year":"2015","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib273","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00296-010-1496-0","article-title":"Pulmonary non-Hodgkin\u2019s lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis","volume":"32","author":"Wang","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.ejmech.2018.09.027_bib274","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s12010-014-0903-5","article-title":"Metabolomics coupled with pattern recognition and pathway analysis on potential biomarkers in liver injury and hepatoprotective effects of yinchenhao","volume":"173","author":"Sun","year":"2014","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib275","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ejmech.2018.09.027_bib276","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0049-0172(99)80026-2","article-title":"The incidence of cancer associated with the treatment of rheumatoid arthritis","volume":"29","author":"Beauparlant","year":"1999","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib277","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2018.09.027_bib278","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000314634","article-title":"Malignancies in autoimmune rheumatic diseases - a mini-review","volume":"57","author":"Szekanecz","year":"2010","journal-title":"Gerontology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib279","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.lungcan.2007.06.013","article-title":"Lung cancer after exposure to disease modifying anti-rheumatic drugs","volume":"59","author":"Bernatsky","year":"2008","journal-title":"Lung Canc."},{"key":"10.1016\/j.ejmech.2018.09.027_bib280","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/tpj.2012.7","article-title":"Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients","volume":"13","author":"Owen","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.ejmech.2018.09.027_bib281","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/ard.62.9.835","article-title":"Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases","volume":"62","author":"Stolt","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib282","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/sarh.2001.27719","article-title":"Cigarette smoking and rheumatoid arthritis","volume":"31","author":"Albano","year":"2001","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib283","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(85)90244-X","article-title":"Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens","volume":"78","author":"Hazleman","year":"1985","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2018.09.027_bib284","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/bmc.3220","article-title":"Ultra-performance liquid chromatography tandem mass spectrometry combined with automated Metabo Lynx analysis approach to screen the bioactive components and their metabolites in Wen-Xin-Formula","volume":"28","author":"Cao","year":"2014","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejmech.2018.09.027_bib285","first-page":"1095","article-title":"Non-Hodgkin\u2019s lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate","volume":"23","author":"Usman","year":"1996","journal-title":"J.\u00a0Rheumatol."},{"issue":"4","key":"10.1016\/j.ejmech.2018.09.027_bib286","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/bmc.3060","article-title":"Serum pharmacochemistry combined with multiple data processing approach to screen the bioactive components and their metabolites in Mutan Cortex by ultra-performance liquid chromatography tandem mass spectrometry","volume":"28","author":"Liu","year":"2014","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejmech.2018.09.027_bib287","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \u201cmethotrexate-associated lymphoproliferative disorders\u201d after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature","volume":"26","author":"Rizzi","year":"2009","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib288","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM198303033080901","article-title":"No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors","volume":"308","author":"Rustin","year":"1983","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib289","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/art.1780160115","article-title":"Toxicity of immunosuppressive drugs in man","volume":"16","author":"Decker","year":"1973","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib290","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000249793","article-title":"Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study","volume":"167","author":"Nyfors","year":"1983","journal-title":"Dermatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib291","first-page":"1172","article-title":"Complications of immunosuppression associated with weekly low dose methotrexate","volume":"18","author":"Shiroky","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"issue":"3","key":"10.1016\/j.ejmech.2018.09.027_bib292","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1074\/mcp.M112.019141","article-title":"Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews","volume":"12","author":"Sun","year":"2013","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ejmech.2018.09.027_bib293","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/art.1780390223","article-title":"Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases","volume":"39","author":"Bachman","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib294","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cca.2012.11.001","article-title":"Salivary proteomics in biomedical research","volume":"415","author":"Zhang","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2018.09.027_bib295","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","article-title":"Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases","volume":"14","author":"Salloum","year":"1996","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib296","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-199920060-00002","article-title":"Lymphoma in patients with rheumatoid arthritis","volume":"20","author":"Georgescu","year":"1999","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.ejmech.2018.09.027_bib297","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2013.11.011","article-title":"Metabolomics in diagnosis and biomarker discovery of colorectal cancer","volume":"345","author":"Zhang","year":"2014","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2018.09.027_bib298","first-page":"1546","article-title":"Primary cutaneous B cell lymphoma during methotrexate therapy for rheumatoid arthritis","volume":"27","author":"Fam","year":"2000","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib299","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cca.2012.12.024","article-title":"Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry","volume":"418","author":"Zhang","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2018.09.027_bib300","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-2265.2006.02529.x","article-title":"Remission of a primary thyroid lymphoma after methotrexate withdrawal","volume":"64","author":"De Mast","year":"2006","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib301","first-page":"2573","article-title":"Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus?","volume":"28","author":"Starkebaum","year":"2001","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib302","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1521-6942(03)00041-X","article-title":"Co-morbidity in rheumatoid arthritis","volume":"17","author":"Mikuls","year":"2003","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib303","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/rheumatology\/kep101","article-title":"Methotrexate, rheumatoid arthritis and infection risk - what is the evidence?","volume":"48","author":"McLean-Tooke","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib304","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib305","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/art.20351","article-title":"Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study","volume":"50","author":"Korpela","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib306","first-page":"1628","article-title":"Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis","volume":"17","author":"Furst","year":"1990","journal-title":"J.\u00a0Rheumatol."},{"issue":"2","key":"10.1016\/j.ejmech.2018.09.027_bib307","first-page":"99","article-title":"Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity","volume":"67","author":"Zhang","year":"2012","journal-title":"Die Pharmazie-An Int. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib308","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/ard.48.3.247","article-title":"Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy","volume":"48","author":"Wallis","year":"1989","journal-title":"Ann. Rheum. Dis."},{"issue":"20","key":"10.1016\/j.ejmech.2018.09.027_bib309","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1039\/c2an35891c","article-title":"Network generation enhances interpretation of proteomics data sets by a combination of two-dimensional polyacrylamide gel electrophoresis and matrix-assisted laser desorption\/ionization-time of flight mass spectrometry","volume":"137","author":"Wang","year":"2012","journal-title":"Analyst"},{"key":"10.1016\/j.ejmech.2018.09.027_bib310","first-page":"1254","article-title":"Pneumocystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis","volume":"18","author":"Flood","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"issue":"28","key":"10.1016\/j.ejmech.2018.09.027_bib311","doi-asserted-by":"crossref","first-page":"17217","DOI":"10.1039\/C7RA00698E","article-title":"Metabolomic applications in hepatocellular carcinoma: toward the exploration of therapeutics and diagnosis through small molecules","volume":"7","author":"Xie","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.09.027_bib312","first-page":"453","article-title":"Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases","volume":"63","author":"Roux","year":"1996","journal-title":"Rev. du Rhum."},{"issue":"25","key":"10.1016\/j.ejmech.2018.09.027_bib313","doi-asserted-by":"crossref","first-page":"14966","DOI":"10.1039\/C6RA28715H","article-title":"Emerging role and recent applications of metabolomics biomarkers in obesity disease research","volume":"7","author":"Zhang","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.09.027_bib314","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1164\/ajrccm.150.1.8025760","article-title":"Opportunistic infection during treatment with low dose methotrexate","volume":"150","author":"Le Mense","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0002-9343(87)90517-1","article-title":"Cryptococcosis associated with low-dose methotrexate for arthritis","volume":"83","author":"Altz-Smith","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib316","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/clinids\/17.4.776","article-title":"Cutaneous cryptococcosis in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate","volume":"17","author":"Frieden","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib317","first-page":"872","article-title":"Pulmonary cryptococcosis mimicking methotrexate pneumonitis","volume":"20","author":"Law","year":"1993","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib318","first-page":"465","article-title":"Pulmonary infections in patients with rheumatoid arthritis","volume":"45","author":"Takayanagi","year":"2007","journal-title":"Nihon Koky\u016bki Gakkai zasshi\u00a0= J. Japanese Respir Soc."},{"key":"10.1016\/j.ejmech.2018.09.027_bib319","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.1780380222","article-title":"Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis","volume":"38","author":"Aglas","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ejmech.2018.09.027_bib320","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12010-014-0955-6","article-title":"Metabolomics approaches and applications in prostate cancer research","volume":"174","author":"Zhang","year":"2014","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib321","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/00007611-199607000-00016","article-title":"Fatal Cytomegalovirus pneumonia in a patient receiving corticosteroids and methotrexate for mixed connective tissue disease","volume":"89","author":"Wallace","year":"1996","journal-title":"South. Med. J."},{"key":"10.1016\/j.ejmech.2018.09.027_bib322","first-page":"1406","article-title":"Herpes simplex hepatitis in a patient with psoriatic arthritis taking prednisone and methotrexate. Report and review of the literature","volume":"18","author":"Aboguddah","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib323","first-page":"1243","article-title":"Disseminated Nocardia brasiliensis infection: an unusual complication of immunosuppressive treatment for childhood dermatomyositis","volume":"18","author":"Klein-Gitelman","year":"1991","journal-title":"J.\u00a0Rheumatol."},{"issue":"5","key":"10.1016\/j.ejmech.2018.09.027_bib324","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s11255-013-0600-2","article-title":"Metabolomics insights into pathophysiological mechanisms of nephrology","volume":"46","author":"Zhang","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib325","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib326","first-page":"287","article-title":"Toxicity of low dose methotrexate in rheumatoid arthritis","volume":"16","author":"\u015awierkot","year":"2007","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib327","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0889-857X(05)70368-9","article-title":"Does methotrexate increase the risk of infection or malignancy?","volume":"23","author":"Kanik","year":"1997","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2018.09.027_bib328","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.autrev.2008.05.001","article-title":"DMARDS and infections in rheumatoid arthritis","volume":"8","author":"Caporali","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejmech.2018.09.027_bib329","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib330","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/ard.2008.094474","article-title":"Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E","volume":"68","author":"Visser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib331","first-page":"895","article-title":"Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study","volume":"33","author":"Idolazzi","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib332","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2014.129","article-title":"Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?","volume":"10","author":"Alsaeedi","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib333","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-eular.5814","article-title":"Methotrexate (MTX) optimal regimen: dose escalation to least at 20Mg\/W or 0.3Mg\/Kg\/W IF remission is not reached is the key factor to get favorable RA outcomes at 1 and 2 Years. Results from the ESPOIR cohort","volume":"73","author":"Gaujoux-Viala","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib334","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib335","first-page":"2521","article-title":"Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients","volume":"29","author":"Sokka","year":"2002","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib336","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A\u00a0randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib337","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib338","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.09.027_bib339","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.autrev.2014.08.026","article-title":"Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an \u201canchor\u201d drug?","volume":"13","author":"Favalli","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejmech.2018.09.027_bib340","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O'Dell","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib341","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/ker084","article-title":"Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective","volume":"50","author":"Schipper","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.09.027_bib342","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clinthera.2014.01.014","article-title":"Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms","volume":"36","author":"Cipriani","year":"2014","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2018.09.027_bib343","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"5","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2018.09.027_bib344","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3899\/jrheum.130738","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"41","author":"Shea","year":"2014","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib345","first-page":"459","article-title":"Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients","volume":"13","author":"Leeb","year":"1995","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib346","first-page":"3420","article-title":"Identification of a highly glycosylated methotrexate membrane Carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport","volume":"51","author":"Matherly","year":"1991","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2018.09.027_bib347","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/art.1780310712","article-title":"The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients","volume":"31","author":"Tishler","year":"1988","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.ejmech.2018.09.027_bib348","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1089\/omi.2014.0112","article-title":"Berberine ameliorates nonbacterial prostatitis via multi-target metabolic network regulation","volume":"19","author":"Sun","year":"2015","journal-title":"OMICS"},{"key":"10.1016\/j.ejmech.2018.09.027_bib349","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/39.10.1102","article-title":"Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?","volume":"39","author":"Griffith","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejmech.2018.09.027_bib350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0049-0172(98)80049-8","article-title":"Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity","volume":"27","author":"Van Ede","year":"1998","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib351","first-page":"34","article-title":"Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the \u201c3E initiative\u201d","volume":"62","author":"De Leonardis","year":"2010","journal-title":"Reumatismo"},{"key":"10.1016\/j.ejmech.2018.09.027_bib352","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib353","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1136\/ard.2009.124065","article-title":"Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study","volume":"69","author":"Bakker","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib354","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/ard.61.8.756","article-title":"Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate","volume":"61","author":"Rozin","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2018.09.027_bib355","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.20","article-title":"Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis","volume":"34","author":"Furst","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib356","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.intimp.2015.08.008","article-title":"Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis","volume":"28","author":"Xiang","year":"2015","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2018.09.027_bib357","first-page":"1","article-title":"Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate","volume":"0","author":"Humphreys","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib358","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10067-016-3243-8","article-title":"Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire)","volume":"35","author":"Fatimah","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib359","first-page":"355","article-title":"Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy","volume":"17","author":"Suwa","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib360","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0272-5231(05)70118-0","article-title":"Pulmonary toxicity of drugs used to treat systemic autoimmune diseases","volume":"19","author":"Libby","year":"1998","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.ejmech.2018.09.027_bib361","first-page":"243","article-title":"Drug-induced pneumonitis: the role of methotrexate","volume":"18","author":"Zisman","year":"2001","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib362","first-page":"1003","article-title":"Protective effect of pentoxyfilline in renal toxicity after methotrexate administration","volume":"15","author":"Asvadi","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib363","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3906\/sag-1408-121","article-title":"Prevention of methotrexate-induced nephrotoxicity by concomitant administration of garlic aqueous extract in rat","volume":"45","author":"Ahmed","year":"2015","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib364","first-page":"387071","article-title":"Curcumin ameliorates methotrexate-induced nephrotoxicity in rats","volume":"2013","author":"Morsy","year":"2013","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/j.ejmech.2018.09.027_bib365","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00467-002-0946-7","article-title":"Effective removal of methotrexate by high-flux hemodialysis","volume":"17","author":"Saland","year":"2002","journal-title":"Pediatr. Nephrol."},{"issue":"11","key":"10.1016\/j.ejmech.2018.09.027_bib366","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1039\/C5FO00489F","article-title":"Metabolomics strategy reveals therapeutical assessment of limonin on nonbacterial prostatitis","volume":"6","author":"Zhang","year":"2015","journal-title":"Food Funct."},{"key":"10.1016\/j.ejmech.2018.09.027_bib367","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3109\/0886022X.2016.1158070","article-title":"Protective effect of propolis on methotrexate-induced kidney injury in the rat","volume":"38","author":"Ulusoy","year":"2016","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ejmech.2018.09.027_bib368","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3109\/0886022X.2015.1074521","article-title":"Quercetin ameliorates methotrexate-induced renal damage, apoptosis and oxidative stress in rats","volume":"37","author":"Erboga","year":"2015","journal-title":"Ren. Fail."},{"issue":"3","key":"10.1016\/j.ejmech.2018.09.027_bib369","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jssc.201500915","article-title":"Characterization of the multiple components of Acanthopanax Senticosus stem by ultra high performance liquid chromatography with quadrupole time-of-flight tandem mass spectrometry","volume":"39","author":"Sun","year":"2016","journal-title":"J.\u00a0Separ. Sci."},{"key":"10.1016\/j.ejmech.2018.09.027_bib370","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3109\/08923973.2014.884135","article-title":"Protective effect of peroxisome proliferator activator receptor (PPAR)-a and -g ligands against methotrexate-induced nephrotoxicity","volume":"36","author":"Ibrahim","year":"2014","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib371","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00393-011-0909-0","article-title":"The other opinion: nephrotoxicity of low-dose methotrexate - a problem which does not exist","volume":"70","author":"Fiehn","year":"2011","journal-title":"Z.\u00a0Rheumatol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib372","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1756-185X.2010.01564.x","article-title":"Low-dose and high-dose methotrexate are two different drugs in practical terms","volume":"13","author":"Malaviya","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib373","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"van Gestel","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib374","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2012-201491","article-title":"Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index","volume":"71","author":"Aletaha","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib375","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/art.21726","article-title":"Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes","volume":"54","author":"Wessels","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib376","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/art.22129","article-title":"Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis","volume":"54","author":"Dervieux","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib377","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/17512433.2015.1077698","article-title":"Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis","volume":"8","author":"Subesinghe","year":"2015","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.027_bib378","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.09.027_bib379","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions","volume":"75","author":"Schett","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib380","article-title":"Phenotypic characterization of nanshi oral liquid alters metabolic signatures during disease prevention","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2018.09.027_bib381","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/ard.56.4.235","article-title":"Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation","volume":"56","author":"ten Wolde","year":"1997","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.09.027_bib382","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/amiajnl-2014-002642","article-title":"Automatic identification of methotrexate-induced liver toxicity in patients with rheumatoid arthritis from the electronic medical record","volume":"22","author":"Lin","year":"2014","journal-title":"J.\u00a0Am. Med. Inf. Assoc."},{"key":"10.1016\/j.ejmech.2018.09.027_bib383","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10067-016-3398-3","article-title":"Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen","volume":"36","author":"Malaviya","year":"2017","journal-title":"Clin. Rheumatol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:47:51Z","timestamp":1759326471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418307992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":383,"alternative-id":["S0223523418307992"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.027","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side effects of methotrexate therapy for rheumatoid arthritis: A\u00a0systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}